Literature DB >> 9817187

Does essential hypertension cause progressive renal disease?

D Fliser1, E Ritz.   

Abstract

In the distant past, terminal renal failure occurred mainly as a result of malignant hypertension. The introduction of effective antihypertensive therapy has made malignant hypertension rare, and researchers have stopped focusing on the kidney's role in their hypertension research. However, recent long-term observational studies have documented an impressive relationship between hypertension and impaired renal function in patients without primary chronic renal disease; elderly and African American individuals with hypertension have the worst prognoses. The hallmark of hypertensive renal injury is thought to be a progressive increase in intrarenal vascular resistance, which may precede changes in renal structure. Because we lack evidence from renal biopsy studies, it is unclear whether an increase in albumin (protein) excretion correlates with these disturbances of renal function and structure. Nevertheless, because urinary excretion of albumin in patients with essential hypertension is related to the risk of cardiovascular complications, its measurement provides important clinical information.

Entities:  

Mesh:

Year:  1998        PMID: 9817187

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

1.  A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension.

Authors:  F Fernández-Vega; J Abellan; S Sanz de Castro; J M Cucalón; B Maceira; A Gómez de la Cámara
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Renal function in the oldest-old on an acute geriatric ward.

Authors:  N J Van den Noortgate; W H Janssens; M B Afschrift; N H Lameire
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

3.  Importance of blood pressure reduction for prevention of progression of renal disease.

Authors:  S C Textor; V J Canzanello
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.